NGM Biopharma 
Welcome,         Profile    Billing    Logout  
 9 Products   0 Diseases   9 Products   5 Trials   435 News 


«123456»
  • ||||||||||  aldafermin (NGM282) / NGM Biopharmaceuticals
    Journal:  FGF19 Analogue as a Surgical Factor Mimetic that Contributes to Metabolic Effects Beyond Glucose Homeostasis. (Pubmed Central) -  Dec 25, 2019   
    P2
    In contrast, administration of NGM282 resulted in rapid, robust and sustained reduction in liver fat content and histology in patients with non-alcoholic steatohepatitis, faithfully replicating another key benefit of bariatric surgery. Our work identifies a strategy for replacing the surgery by an equally effective, but less invasive, treatment for non-alcoholic steatohepatitis (This trial is registered with clinicaltrials.gov, number NCT01943045).
  • ||||||||||  NGM395 / NGM Biopharma
    New P1 trial:  Study of NGM395 in Adult Participants (clinicaltrials.gov) -  Dec 4, 2019   
    P1,  N=80, Not yet recruiting, 
  • ||||||||||  NGM120 / NGM Biopharma
    Trial completion:  Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects (clinicaltrials.gov) -  Aug 19, 2019   
    P1,  N=92, Completed, 
    This is one of the largest stool microbiome profiling report on the response to a therapeutic agent in patients with NASH. Recruiting --> Completed
  • ||||||||||  elafibranor (GFT505) / Genfit, Ocaliva (obeticholic acid) / Intercept, NGM282 / NGM Biopharmaceuticals
    Journal:  Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. (Pubmed Central) -  Jul 13, 2019   
    Patients with NAFLD have a significant increase in cardiovascular disease risk. For biopsy-proven NASH, vitamin E and pioglitazone are the recommended medical treatments in addition to lifestyle modification.
  • ||||||||||  MK-3655 / Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date:  Study of NGM313 in Obese Participants (clinicaltrials.gov) -  Mar 13, 2019   
    P1b,  N=25, Completed, 
    For biopsy-proven NASH, vitamin E and pioglitazone are the recommended medical treatments in addition to lifestyle modification. Recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Enrollment change, Trial completion date, Trial primary completion date:  Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) -  Jun 6, 2018   
    P2,  N=250, Recruiting, 
    Further study of NGM282 is warranted in this patient population. N=140 --> 250 | Trial completion date: Apr 2018 --> Sep 2019 | Trial primary completion date: Apr 2018 --> Sep 2019
  • ||||||||||  NGM120 / NGM Biopharma
    Enrollment open:  Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects (clinicaltrials.gov) -  Apr 5, 2018   
    P1,  N=98, Recruiting, 
    N=140 --> 250 | Trial completion date: Apr 2018 --> Sep 2019 | Trial primary completion date: Apr 2018 --> Sep 2019 Not yet recruiting --> Recruiting
  • ||||||||||  MK-3655 / Merck (MSD)
    New P1 trial:  Study of NGM313 in Obese Participants (clinicaltrials.gov) -  Oct 1, 2017   
    P1b,  N=30, Recruiting, 
  • ||||||||||  MK-3655 / Merck (MSD)
    Trial completion:  Phase 1 Study of NGM313 in Healthy Adult Participants (clinicaltrials.gov) -  Sep 14, 2017   
    P1,  N=151, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Enrollment open, Enrollment change, Trial primary completion date:  Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) -  Mar 13, 2017   
    P2,  N=140, Recruiting, 
    Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Dec 2016 --> Apr 2018
  • ||||||||||  MK-3655 / Merck (MSD)
    Enrollment closed:  Phase 1 Study of NGM313 in Healthy Adult Participants (clinicaltrials.gov) -  Mar 9, 2017   
    P1,  N=183, Active, not recruiting, 
    Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Dec 2016 --> Apr 2018 Recruiting --> Active, not recruiting
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial completion, Enrollment change, Trial primary completion date:  Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals (clinicaltrials.gov) -  Feb 1, 2017   
    P1/2,  N=31, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=60 --> 31 | Trial primary completion date: Sep 2017 --> Jan 2017
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) -  Aug 24, 2016   
    P2b,  N=36, Completed, 
    Recruiting --> Completed | N=60 --> 31 | Trial primary completion date: Sep 2017 --> Jan 2017 Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Enrollment closed:  Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) -  Aug 24, 2016   
    P2,  N=80, Active, not recruiting, 
    Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016 Recruiting --> Active, not recruiting
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial primary completion date:  Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) -  Nov 17, 2015   
    P2,  N=75, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Dec 2016
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial completion:  Phase 2 Study of NGM282 in Patients With Type 2 Diabetes (clinicaltrials.gov) -  Nov 18, 2014   
    P2,  N=81, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Enrollment closed:  Phase 2 Study of NGM282 in Patients With Type 2 Diabetes (clinicaltrials.gov) -  Jul 30, 2014   
    P2,  N=80, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Enrollment open:  Phase 2 Study of NGM282 in Patients With Type 2 Diabetes (clinicaltrials.gov) -  Sep 24, 2013   
    P2,  N=80, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting